Imogene Dunn
- Physiology
- Molecular Biology
- Endocrinology, Diabetes and Metabolism
- Clinical Biochemistry top 10%
- Surgery
- Co-authors
- Carmen ValcarceAaron H. BursteinL. AltstielMarwan N. SabbaghJohn B. BuseAdrian VellaKit A. KellerJules T. Mitchel
- Topics
- Advanced Glycation End Products research (5 papers)Alzheimer's disease research and treatments (4 papers)Pancreatic function and diabetes (3 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Imogene Dunn
14 papers receiving 228 citations
Peers
Comparison fields: 5 of 60
- Physiology 81
- Molecular Biology 68
- Endocrinology, Diabetes and Metabolism 63
- Clinical Biochemistry 61
- Surgery 52
Countries citing papers authored by Imogene Dunn
This map shows the geographic impact of Imogene Dunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Imogene Dunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Imogene Dunn more than expected).
Fields of papers citing papers by Imogene Dunn
This network shows the impact of papers produced by Imogene Dunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Imogene Dunn. The network helps show where Imogene Dunn may publish in the future.
Co-authorship network of co-authors of Imogene Dunn
This figure shows the co-authorship network connecting the top 25 collaborators of Imogene Dunn. A scholar is included among the top collaborators of Imogene Dunn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Imogene Dunn. Imogene Dunn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 7 | |
| 3 | 4 | |
| 4 | 49 | |
| 5 | 4 | |
| 6 | 5 | |
| 7 | 4 | |
| 8 | 118 | |
| 9 | Query Effectiveness in Light of Risk-Based Monitoring (RBM) | 1 |
| 10 | 1 | |
| 11 | 1 | |
| 12 | 4 | |
| 13 | 17 | |
| 14 | 15 | |
| 15 | 8 |
About Imogene Dunn
Imogene Dunn is a scholar working on Clinical Biochemistry, Endocrinology, Diabetes and Metabolism and Physiology, having authored 15 papers that have together received 238 indexed citations. Recurring topics across this work include Advanced Glycation End Products research (5 papers), Alzheimer's disease research and treatments (4 papers) and Pancreatic function and diabetes (3 papers). The work is most often cited by research in Clinical Biochemistry (61 citations), Biological Psychiatry (11 citations) and Endocrinology, Diabetes and Metabolism (63 citations). Imogene Dunn has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Carmen Valcarce, Aaron H. Burstein, L. Altstiel, Marwan N. Sabbagh, John B. Buse, Adrian Vella, Kit A. Keller, Jules T. Mitchel, Yong Joong Kim and Larry D. Altstiel. Their work appears in journals such as Diabetes, Science Translational Medicine and Experimental Biology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.